(Q39452113)

English

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Anthony Mato

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Tatyana Feldman

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Tania Zielonka

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Arun Singavi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gabriella Gadaletta

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kathryn Waksmundzki

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Pritish Bhattacharyya

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kar Fai Chow

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Xiao Yang

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

David Panush

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Harry Agress

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Maria Rosario

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Christina Howlett

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Andrew Pecora

14

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Andre Goy

15

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

15 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

2606-2612

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Prognostic biomarkers in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.783909

21 January 2018

Identifiers

10.3109/10428194.2013.783909

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39452113&oldid=1568018626"